Abeona Therapeutics Inc. Quarterly report pursuant to Section 13 or 15(d)

Stock Based Option Compensation and Restricted Stock Compensation (Tables)

3 Months Ended

Mar. 31, 2018

The following table summarizes stock-based compensation for the three months ended March 31, 2018 and 2017:

	Three months ended
	March 31,
	2018		2017
Research and development	$	1,056,000	$	356,000
General and administrative		844,000		1,136,000
Stock-based compensation expense included in operating expense	$	1,900,000	$	1,492,000

The following table summarizes restricted common stock compensation expense for the three months ended March 31, 2018 and 2017:

	Three months ended
	March 31,
	2018		2017
Research and development	$	-	$	-
General and administrative		172,000		362,000
Stock-based compensation expense included in operating expense	$	172,000	$	362,000